

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes. Consultation comments identified potential equality issues.

1. Current therapies which act on gonadotropin releasing hormone pathways may not be available to people who are trans or non-binary
2. Current therapies which act on gonadotropin releasing hormone pathways may not be available to those with particular historic or cultural beliefs that do not wish to take hormone add-back therapy.
3. Uterine fibroids are more prevalent in those from Black African or Caribbean family backgrounds.
4. Linzagolix would provide a broader treatment option with increased dosing flexibility that may benefit communities such as those from Black African or Caribbean family backgrounds who have historically seen inequalities in access to specialist healthcare
5. Linzagolix may benefit those from lower socioeconomic groups for whom current clinic visits can be expensive and create barriers to uptake.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.

The committee will consider all other potential equality issues during the course of this appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Yes the scope has been amended to reference the higher prevalence in those from Black African or Caribbean family backgrounds.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Ian Watson

Date: 22/06/2023